Metavention is a venture-backed medical device company founded in 2012 and based in Minneapolis, Minnesota and Orange County, California. The company is leveraging its unique insights into the role of the sympathetic nervous system in diabetes pathophysiology to develop therapies with the potential to transform the treatment of type 2 diabetes. Metavention has assembled a world-class team of engineers, scientists, clinicians and investors to pursue its mission to improve the lives and health of people with type 2 diabetes.
Chief Executive Officer
Todd Berg is the CEO of Metavention, Inc. Todd was previously President and CEO of Torax Medical which he co-founded and was then acquired by Johnson & Johnson. Prior to Torax Medical, Todd was with St. Jude Medical where he was the Vice President of Emerging Technology. He joined St. Jude Medical through the acquisition of Vascular Science in 1999 where he was the Vice President of Research and Development. Prior to Vascular Science he was with SciMed Life Systems and Boston Scientific.
President, Chief Medical Officer, and Founder
Bobby Azamian is the Founder, President and Chief Medical Officer of Metavention. Bobby joined Versant Ventures in 2011, and while at Versant founded Metavention and served as its first President and Chief Executive Officer. Prior to joining Versant, Bobby was a Senior Associate at Third Rock Ventures, where he was actively involved in the building and launch of the firm’s first medical device companies. Previously, Bobby completed residency in internal medicine and practiced as a hospitalist at Brigham and Women’s Hospital while on the faculty of Harvard Medical School. Bobby holds an MD from the Harvard-MIT Division of Health Sciences and Technology; a DPhil in Chemistry from Oxford University as a Rhodes Scholar; and a BA in Physics from Rice University.
The Metabolic Neuromodulation System is not currently approved in any region and is limited to investigational use only for the COMPLEMENT study. CAUTION: INVESTIGATIONAL DEVICE, LIMITED TO INVESTIGATIONAL USE.